Table 3 Multivariate Cox proportional hazard analysis

From: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

Variable	Overall survival		Relapse-free survival
Variable	HR (95% Cl)	p	HR (95% Cl)	p
CA125	1 (1–1)	0.495	1 (1–1)	0.98
Stage		0.5		0.98
Stage I	1		1
Stage II	0.76 (0.14–4.18)	0.755	1.3 (0.45–3.77)	0.627
Stage III	2.21 (0.76–6.41)	0.145	1.75 (0.79–3.87)	0.165
Stage IV	4.89 (1.33–17.9)	0.017	2.84 (0.96–8.4)	0.06
Debulking		0.39		0.9
Debulking R0	1		1
Debulking R1	0.62 (0.21–1.84)	0.386	0.95 (0.4–2.24)	0.91
Debulking R2	1.35 (0.8–2.27)	0.262	1.92 (1.21–3.06)	0.006
Age	1 (0.98–1.03)	0.743	1.01 (0.99–1.03)	0.508
CALR	0.96 (0.94–0.99)	0.0003	0.97 (0.96–0.99)	0.002
DC-LAMP summary	0.8 (0.7–0.91)	0.001	0.97 (0.94–1.0)	0.12
CD8 summary	0.99 (0.99–0.99)	0.0007	0.99 (0.99–1)	0.13
CD20	0.23 (0.3–1.54)	0.13	1 (0.33–1.5)	0.86
NKp46	1.08 (0.9–1.3)	0.37	1.11 (0.93–1.35)	0.24

Back to article page